share_log
Benzinga ·  May 1 06:38
Kalvista Pharmaceuticals Announced Its Strategic Plans For Fiscal Year 2025, Beginning May 1, Including For Sebetralstat, The Company's Investigational Novel, Oral Plasma Kallikrein Inhibitor For The On-demand Treatment Of Hereditary Angioedema
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment